Education and Training
- Fellow in Cardiology, Medicine, Duke University, 1998 - 2004
- Medical Resident, Medicine, Duke University, 1995 - 1998
- M.D., Harvard University , 1995
Marquis-Gravel, Guillaume, Zhen Huang, Steven L. Zelenkofske, A Michael Lincoff, Roxana Mehran, P Gabriel Steg, Christoph Bode, John H. Alexander, and Thomas J. Povsic. “Interplay between PCI access site, anticoagulant agent, and bleeding: Insights from the REGULATE-PCI randomized trial.” American Heart Journal 223 (February 24, 2020): 84–86. https://doi.org/10.1016/j.ahj.2020.02.013.
Shavadia, Jay S., Christopher B. Granger, Wendimagegn Alemayehu, Cynthia M. Westerhout, Thomas J. Povsic, Sorin J. Brener, Sean van Diepen, Christopher Defilippi, and Paul W. Armstrong. “High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarction.” Am Heart J 220 (February 2020): 137–44. https://doi.org/10.1016/j.ahj.2019.09.015.
Ward, Rachael, Zhen Huang, Frank W. Rockhold, Iris Baumgartner, Jeffrey S. Berger, Juuso I. Blomster, F Gerry R. Fowkes, et al. “Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial.” Am Heart J 220 (February 2020): 51–58. https://doi.org/10.1016/j.ahj.2019.11.007.
Povsic, Thomas J., E Magnus Ohman, Matthew T. Roe, Jennifer White, Frank W. Rockhold, Gilles Montalescot, Jan H. Cornel, et al. “P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes.” In Jama Cardiol, 4:680–84, 2019. https://doi.org/10.1001/jamacardio.2019.1510.
Normand, Camilla, David M. Kaye, Thomas J. Povsic, and Kenneth Dickstein. “Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology.” Lancet 393, no. 10175 (March 9, 2019): 1045–55. https://doi.org/10.1016/S0140-6736(18)32216-5.
Fanaroff, Alexander C., Robert Clare, Karen S. Pieper, Kenneth W. Mahaffey, Chiara Melloni, Jennifer B. Green, John H. Alexander, et al. “Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials.” Circulation 139, no. 7 (February 12, 2019): 863–73. https://doi.org/10.1161/CIRCULATIONAHA.118.037202.
Hernandez, Adrian F., Jennifer B. Green, Salim Janmohamed, Ralph B. D’Agostino, Christopher B. Granger, Nigel P. Jones, Lawrence A. Leiter, et al. “Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.” Lancet 392, no. 10157 (October 27, 2018): 1519–29. https://doi.org/10.1016/S0140-6736(18)32261-X.
Fanaroff, Alexander C., Valarie Morrow, Mitchell W. Krucoff, Jonathan H. Seltzer, Emerson C. Perin, Doris A. Taylor, Leslie W. Miller, et al. “A Path Forward for Regenerative Medicine.” Circ Res 123, no. 4 (August 3, 2018): 495–505. https://doi.org/10.1161/CIRCRESAHA.118.313261.
Henry, Timothy D., Douglas W. Losordo, Jay H. Traverse, Richard A. Schatz, E Marc Jolicoeur, Gary L. Schaer, Robert Clare, et al. “Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials.” Eur Heart J 39, no. 23 (June 14, 2018): 2208–16. https://doi.org/10.1093/eurheartj/ehx764.